Strong Performance by Surgery Partners in Third Quarter
Surgery Partners, Inc. (NASDAQ: SGRY), a leading owner and operator of short-stay surgical facilities, showcased its robust performance with significant advancements in the latest financial quarter. Despite challenges, the company reported an impressive 6.6% growth in revenue for the third quarter compared to the previous year, highlighting its resilience and strategic operations.
Highlights of Third Quarter 2025
As the third quarter concluded, Surgery Partners released financial data that underscores its remarkable progress. The company achieved revenue of $821.5 million, a commendable increase from $770.4 million during the same quarter last year. Notably, revenues from same-facility surgical procedures grew by 6.3%, reflecting the rising demand for its services.
Operating Metrics Showcase Positive Trajectory
The quarter also revealed a 2.1% increase in total surgical cases, with same-facility cases rising by 3.4%. This uptick is indicative of the company's expanding operational capacity and its commitment to meeting patient needs with quality surgical care. While Surgery Partners did report a net loss of $22.7 million, its Adjusted EBITDA saw a 6.1% increase to $136.4 million, showcasing the effectiveness of its operational strategies.
Guidance and Growth Strategy
The company's financial guidance for the remainder of 2025 has been adjusted, reflecting a prudent outlook due to volume trends. Total revenue and Adjusted EBITDA for the full year are now projected to range between $3.275 billion to $3.30 billion and $535 million to $540 million, respectively. CEO Eric Evans emphasized the company's focus on operational excellence and disciplined capital allocation to foster long-term growth.
Operational Resilience Amidst Market Dynamics
Despite encountering softer volume and payor mix trends, Surgery Partners maintained confidence in its robust business model. CFO Dave Doherty noted the resilience demonstrated by the company's team and indicated that the revised full-year outlook reflects a careful approach in anticipation of evolving market conditions. The strategic evaluations of M&A opportunities further exhibit Surgery Partners’ intent to maximize its portfolio.
Financial Overview and Liquidity Position
Examining the year-to-date results for 2025, Surgery Partners recorded revenues of $2.423 billion, marking a 7.7% increase from $2.249 billion reported in 2024. This performance aligns with the company's strategic aspirations, with an increase of 5.4% in same-facility revenues alongside a sustained growth in cash flows from operations, which totaled $170.9 million compared to $188.7 million in the previous year.
Solid Liquidity and Debt Management
As of September 30, 2025, Surgery Partners boasted cash and cash equivalents of $203.4 million, bolstered by a borrowing capacity of $405.9 million under its revolving credit facility. The company continues to maintain a focus on strategic debt management, with a ratio of total net debt to EBITDA at approximately 4.2x, indicating a solid financial footing amidst the industry's challenges.
What Lies Ahead?
Moving forward, the company plans to leverage its strong operational foundation to convert strategic opportunities for further growth. With an intensive focus on expanding its network of surgical facilities and optimizing existing operations, Surgery Partners remains positioned to capitalize on the increasing demand for outpatient surgical services. The healthcare landscape continues to evolve rapidly, and the company is dedicated to adaptability and innovation to ensure sustained success in the future.
Frequently Asked Questions
What were the financial highlights for Surgery Partners in Q3 2025?
Surgery Partners reported a revenue increase of 6.6%, totaling $821.5 million, and an Adjusted EBITDA of $136.4 million, marking a 6.1% increase.
How does the company plan to address market challenges?
The company is focused on operational excellence and disciplined capital deployment to navigate market dynamics and ensure sustained growth.
What is the updated guidance for full year 2025?
Surgery Partners has projected the full year 2025 revenue in the range of $3.275 billion to $3.30 billion and Adjusted EBITDA between $535 million and $540 million.
How has liquidity changed for Surgery Partners?
The company reported cash and cash equivalents of $203.4 million with borrowing capacity of $405.9 million as of September 30, 2025.
What strategic opportunities is Surgery Partners exploring?
The company continues to evaluate M&A opportunities to optimize its portfolio and drive long-term growth.
